Yekeduz, E. Et Al. 2021. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6 .

Yekeduz, E., Erturk, I., Tural, D., Karadurmus, N., Karakaya, S., Hizal, M., ... Arslan, C.(2021). Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

Yekeduz, EMRE Et Al. "Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Yekeduz, EMRE Et Al. "Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Yekeduz, E. Et Al. (2021) . "Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

@article{article, author={EMRE YEKEDÜZ Et Al. }, title={Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}